Track Dr. Reddy's Laboratories live share price with 52 week high and low, chart views, quick fundamentals, business segments, financial highlights, peer comparison, dividends, bonuses/splits and FAQs.
Switch between 1 Day, 5 Day, 1 Month and 1 Year views. The chart uses Yahoo Finance-compatible NSE data.
Use these market-feed values as a starting point. Verify the latest price, 52 week range, valuation ratios, dividends and corporate actions from NSE, BSE and company filings.
Dr. Reddy's Laboratories Ltd is a Hyderabad-headquartered pharmaceutical company focused on affordable and innovative medicines. Its portfolio includes active pharmaceutical ingredients, generics, branded generics, biosimilars, over-the-counter products and pharmaceutical services.
For customers, medicine use should always be guided by a qualified doctor, pharmacist and approved product label. For investors, the business is tracked through revenue growth, margins, research pipeline, regulatory compliance, geographic mix and cash generation.
The company reports Global Generics, Pharmaceutical Services and Active Ingredients, and Others. Segment mix matters because generics, APIs, consumer health and biosimilars can have different growth, margin and regulatory profiles.
Dr. Reddy's Laboratories makes money by developing, manufacturing and selling pharmaceutical products and services. The Global Generics business sells finished medicines, branded generics, OTC products and biologics. The PSAI business supplies APIs, intermediates and pharmaceutical services to other pharmaceutical customers.
Important drivers include product launches, regulatory approvals, manufacturing quality, R&D productivity, price erosion, currency movement, acquisition integration and cash conversion. This page is educational and avoids buy or sell recommendations.
FY25 segment values below are rounded for beginner-friendly reading. Verify exact values and latest definitions from the annual report and exchange filings.
| Business / geography | FY 2024 revenue | FY 2025 revenue | Beginner explanation |
|---|---|---|---|
| Global Generics | ₹24,545 Cr | ₹28,955 Cr | Finished generics, branded generics, OTC products and biologics |
| North America within Global Generics | ₹12,990 Cr | ₹14,516 Cr | Large market; monitor product approvals and price erosion |
| India within Global Generics | ₹4,641 Cr | ₹5,373 Cr | Domestic branded generics, vaccines and prescription portfolio |
| Europe within Global Generics | ₹2,051 Cr | ₹3,588 Cr | Includes base business and acquired consumer-health revenues |
| Emerging Markets within Global Generics | ₹4,864 Cr | ₹5,477 Cr | Russia, CIS, Romania and other markets |
| PSAI | ₹2,980 Cr | ₹3,385 Cr | Active pharmaceutical ingredients and pharmaceutical services |
| Others | ₹391 Cr | ₹214 Cr | Smaller and emerging businesses; verify latest notes |
These simplified highlights are for education. Use official filings for audited figures, accounting notes and restatements.
| Particulars | FY 2024 | FY 2025 | Investor note |
|---|---|---|---|
| Revenue from operations | ₹27,916 Cr | ₹32,554 Cr | Verify final audited figures from annual report |
| EBITDA | ₹8,300 Cr | ₹9,210 Cr | Operating measure before depreciation, interest and tax |
| Profit before tax | ₹7,187 Cr | ₹7,678 Cr | Compare with revenue growth and margin trend |
| Profit attributable to equity holders | ₹5,539 Cr | ₹5,650 Cr | Net profit can be affected by pricing, mix and impairments |
| Diluted EPS | ₹66.39 | ₹67.78 | Check adjustment after any corporate action |
| R&D expense / revenue | 8.2% | 8.4% | Supports complex generics, biosimilars and pipeline |
The balance sheet helps investors understand assets, working capital, intangibles, net cash or debt and equity base.
| Particulars | Mar 2024 | Mar 2025 | Investor note |
|---|---|---|---|
| Property, plant and equipment | ₹7,689 Cr | ₹9,776 Cr | Manufacturing and development asset base |
| Intangibles | ₹3,695 Cr | ₹9,680 Cr | Monitor acquisition and impairment risk |
| Inventories | ₹6,355 Cr | ₹7,109 Cr | Important for supply and launch readiness |
| Trade receivables | ₹8,030 Cr | ₹9,042 Cr | Track collection cycle and working capital |
| Operating working capital | — | ₹12,598 Cr | Company-reported non-GAAP measure |
| Net cash surplus | — | ₹2,454 Cr | Can support R&D, acquisitions and dividends |
Cash flow explains how much cash the business generated, how much was spent on assets and how acquisitions affected final cash position.
| Particulars | FY 2025 | What it means |
|---|---|---|
| Net cash from operating activities | ₹6,642 Cr | Core cash generated by business operations |
| Taxes paid | ₹1,999 Cr | Cash tax outflow affects conversion |
| Investment in PPE and intangibles | ₹3,315 Cr | Capex for manufacturing, products and expansion |
| Free cash flow before acquisitions | ₹1,327 Cr | Compare with net profit for earnings quality |
| Acquisition-related payout | ₹5,310 Cr | Cash used for acquired businesses or portfolios |
| Cash flow after acquisition payout | -₹3,982 Cr | Verify latest period from filings |
Ratios help compare business quality and valuation, but they should be read along with product pipeline, regulatory history and cash conversion.
| Metric | FY 2024 | FY 2025 | How to read it |
|---|---|---|---|
| Gross margin | 58.6% | 58.5% | Shows product and cost mix |
| EBITDA margin | 29.7% | 28.3% | Track operating profitability |
| PBT margin | 25.7% | 23.6% | Compare with peers and product cycles |
| PAT margin | 19.9% | 17.4% | Net margin after tax |
| RoCE | — | 27.7% | Verify company methodology |
| Net debt to equity | — | -0.07x | Negative value indicates net cash surplus |
Use these items as a checklist while reading quarterly results, annual reports and exchange filings.
Peer comparison uses selected Indian pharmaceutical companies. Verify current values from NSE, BSE or your broker platform if the external quote feed is unavailable.
| Company | Yahoo symbol | Price | Market Cap | P/E | 52W High / Low | Dividend Yield |
|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories | DRREDDY.NS | — | — | — | — | — |
| Sun Pharmaceutical Industries | SUNPHARMA.NS | — | — | — | — | — |
| Cipla | CIPLA.NS | — | — | — | — | — |
| Lupin | LUPIN.NS | — | — | — | — | — |
| Zydus Lifesciences | ZYDUSLIFE.NS | — | — | — | — | — |
| Aurobindo Pharma | AUROPHARMA.NS | — | — | — | — | — |
| Year | Dividend Detail | Note |
|---|---|---|
| FY 2024-25 | Past dividend history should be verified from official filings | Check amount, record date and payment date from NSE/BSE |
| FY 2023-24 | Past dividend history available in company and exchange records | Use official corporate-action records for exact entitlement |
| FY 2022-23 | Past dividend history available in company and exchange records | Do not rely only on third-party summaries |
| Action | Detail | Note |
|---|---|---|
| Bonus issue | No live entitlement assumed on this page | Verify any bonus announcement from NSE/BSE filings |
| Stock split | No live entitlement assumed on this page | Verify split history and face value from filings |
| Face value | ₹1 per equity share is commonly reported by market portals | Confirm from latest exchange/company filing |
Important: dividend, bonus, split, record date, ex-date and face value details must be verified from official NSE, BSE and company filings before use.
These FAQs answer common AI-search-style questions about the company, products, business model, share price, risks, dividends and investor monitorables.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that sells generics, branded generics, APIs, biosimilars, OTC products and pharmaceutical services.
The NSE symbol is DRREDDY and the Yahoo Finance-compatible symbol used here is DRREDDY.NS. The BSE code is 500124.
It earns revenue from finished medicines through Global Generics, APIs and pharmaceutical services through PSAI, and selected emerging businesses.
Key risks include USFDA observations, generic price erosion, delayed approvals, litigation, product concentration, currency movement and acquisition integration.
The company has paid dividends in the past, but users should verify the latest dividend, record date and payout from official exchange filings.
No. Generics are a large part of the business, but it also has branded generics, APIs, biosimilars, OTC products and pharmaceutical services.
Common Indian pharma peers include Sun Pharma, Cipla, Lupin, Zydus Lifesciences and Aurobindo Pharma.
No. This page is educational and does not provide buy, sell or hold recommendations.
